Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMICUS THERAPEUTICS, INC. Director's Dealing 2021

Jun 17, 2021

31523_dirs_2021-06-17_7dc61eea-a307-4789-8925-31b322468d03.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2021-06-15

Reporting Person: Crowley John F (Director, Chairman & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-15 Common Stock M 22000 $4.38 Acquired 899230 Direct
2021-06-15 Common Stock S 22000 $10.256 Disposed 877230 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-15 Stock Options (right to buy) $4.38 M 22000 Disposed 2022-06-04 Common Stock (22000) Direct
2021-06-16 Stock Options (right to buy) $11.19 G 230000 Disposed 2025-01-02 Common Stock (230000) Direct
2021-06-16 Stock Options (right to buy) $15.96 G 230000 Disposed 2025-06-01 Common Stock (230000) Direct
2021-06-16 Stock Options (right to buy) $11.74 G 250000 Disposed 2026-01-04 Common Stock (250000) Direct
2021-06-16 Stock Options (right to buy) $5.13 G 6889 Disposed 2027-01-03 Common Stock (6889) Direct
2021-06-16 Stock Options (right to buy) $15.67 G 131580 Disposed 2028-01-03 Common Stock (131580) Direct
2021-06-16 Stock Options (right to buy) $10.04 G 216351 Disposed 2029-01-02 Common Stock (216351) Direct
2021-06-16 Stock Options (right to buy) $9.55 G 142872 Disposed 2030-01-02 Common Stock (142872) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 64895 Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.13 to $10.69 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of these options were fully vested and exercisable as of the transaction date.

F4: The gift of vested options reported on this Form 4 were made to the John F. Crowley 2021 Family Trust for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the trust.